Published Research and Presentations

Overall survival (OS) Results of a Phase III Randomized Trial of Standard of Care Therapy with or without enzalutamide for a Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP –led International Co-operative Group Trial

ENZAMET

MOGA ASM

16/08/2019

Professor Ian D. Davies

“Discrepancies in registry Coding for Penile cancer” and “The significance of demographic location in survival outcomes”.

Other

USANZ ASM

14/02/2019

Dr Simeon Ngweso – Villas Marshall Prize Winner, Penile cancer in Western Australia

P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs)

P3BEP

Clinical Oncology Society of Australia

13/11/2017

Nayar N, Lawrence N, Stockler M, Martin A, Yip S, Wong N, Yeung A, Friedlander M, Mazhar D, Pashankar F, Quinn D, Walker R, Winstanley M, Hanning F, Weickhardt A, Stevanovic A, Davis I, Toner G, Grimison P.